

Alex J. Mayer  
Cabinet Secretary

Cynthia Beane, MSW, LCSW  
Commissioner

## *Pharmaceutical and Therapeutics Committee*

**October 29<sup>th</sup>, 2025**

Location: In person –  
St John XXIII Pastoral Center  
100 Hodges Road  
Charleston, WV 25314  
(304) 558-1700

Time: Open Session 9:00 AM – 10:30 AM EST

Time: Executive Session 10:30 AM – 1:30 PM EST

Time: Open Session 1:30 PM – 5:00 PM EST

### **AGENDA**

Therapeutic Class List on Pages 3 and 4

- I. Call to Order – **Open Session (Approximately 9:00 AM – 10:30 AM)** *\*times may vary depending on number of public speakers as well as any additional discussion*  
Call in information for the Open Session is +1 952-222-7450 meeting code 273 427 629#
- II. Welcome and Introductions
- III. Housekeeping Items/Updates
  - a. Approval of the August 27<sup>th</sup>, 2025, Minutes
  - b. PDL Compliance/Generic Percent Report Updates
- IV. Drug Class Announcements
- V. Chairman Calls for First Round of Extractions
- VI. Public Comments (*Agenda classes only - limit three minutes per product*)
  - a. Speaker Sign-up will begin one hour prior to the start of the P&T Committee meeting (8:00am EST) and will conclude after 45 minutes. Additional information may be found on the WV BMS website under P&T Committee > Speaker Sign-Up Process

[Pharmaceutical and Therapeutics Committee | Bureau for Medical Services](#)



- VII. Chairman Calls for Second Round of Extractions
- VIII. Motion for All Non-Extracted Categories to be Approved as Proposed
- IX. **Executive Session (Approximately from 10:30 AM-1:30 PM)**
- X. Lunch Break; approximately 12:30 PM – 1:30 PM
- XI. Extracted Therapeutic Category Reviews/Committee Recommendations (**Approximately 1:30 PM – 5:00 PM/Meeting Adjournment**)  
\*Please use the original information for joining the call remotely: Call in information for the Open Session is +1 952-222-7450 meeting code 273 427 629#
- XII. Next Meeting – January 28<sup>th</sup>, 2026, 2:00 PM - 5:00 PM, Virtual Meeting
- XIII. Other Business
- XIV. Adjournment



Therapeutic Class Reviews recommended by CHC for first round extraction are denoted in ***bold, italic*** font.

1. Acne Agents, Topical
2. Alzheimer's Agents
3. Analgesics, Narcotics- Long Acting (Non-Parenteral)
4. Analgesics, Narcotics- Short Acting (Non-Parenteral)
- 5. *Androgenic Agents***
6. Anesthetics, Topical
- 7. *Angiotensin Modulators***
8. Antianginal & Anti-Ischemic
9. Antibiotics, GI & Related Agents
- 10. *Antibiotics, Inhaled***
11. Antibiotics, Topical
12. Antibiotics, Vaginal
13. Anticoagulants
- 14. *Anticonvulsants***
15. Antidepressant, Other
16. Antidepressants, SSRIs
- 17. *Antiemetics***
18. Antifungals, Oral
19. Antifungals, Topical
20. Antihemophilia Factor Agents
21. Antihypertensives, Sympatholytics
22. Antihyperuricemics
23. Antimigraine Agents, Prophylaxis
- 24. *Antimigraine Agents, Acute***
- 25. *Antiparasitics, Topical***
26. Antiparkinson's Agents
27. Antipsoriatics, Topical
- 28. *Antipsychotics, Atypical***
- 29. *Antiretrovirals***
- 30. *Antivirals, Oral***
- 31. *Antivirals, Topical***
- 32. *Beta Blockers***
33. Bladder Relaxant Preparations
- 34. *Bone Resorption Suppression & Related Agents***
35. BPH Treatments
36. Bronchodilators, Beta Agonists
37. Calcium Channel Blockers
38. Cephalosporins & Related Antibiotics
- 39. *COPD Agents***
40. Crohn's Disease Oral Steroids
- 41. *Cytokine & Cam Antagonists***
42. Diabetes Agents, Biguanides
- 43. *Diabetes Agents, DPP-4 Inhibitors***
44. Diabetes Agents, GLP-1 Agonists
45. Diabetes Agents, Insulin and Related Agents
46. Diabetes Agents, Meglitinides
47. Diabetes Agents, Miscellaneous Agents
- 48. *Diabetes Agents, SGLT2 Inhibitors***
49. Diabetes Agents, TZD
- 50. *Dry Eye Products***
- 51. *Duchenne Muscular Dystrophy (DMD), Corticosteroids***
52. Epinephrine, Self-Injected
53. Erythropoiesis Stimulating Proteins
54. Fluoroquinolones, Oral
55. Glucocorticoids, Inhaled
56. Growth Hormones and Achondroplasia Agents
57. H. Pylori Treatment
- 58. *Heart Failure Treatments***
59. Hepatitis B Treatments
60. Hepatitis C Treatments
61. Hyperparathyroid Agents
62. Hyperphosphatemia Agents
63. Hypoglycemia Treatments
- 64. *Immunomodulators, Atopic Dermatitis***
65. Immunomodulators, Genital Warts & Actinic Keratosis Agents
66. Immunosuppressive, Oral
67. Intranasal Rhinitis Agents
68. Irritable Bowel Syndrome/Short Bowel Syndrome/Selected GI Agents
69. Laxatives and Cathartics
70. Leukotriene Modifiers
71. Lipotropics, Other (Non-Statins)
72. Lipotropics, Statins
73. MABS – Anti-IL/IgE
74. Major Cardiovascular Event (MACE) Reduction Agents, GLP-1 Agonists
75. Macrolides



- 76. Metabolic Dysfunction- Associated Steatohepatitis (MASH)
- 77. Multiple Sclerosis Agents
- 78. Neuropathic Pain
- 79. NSAIDs
- 80. Obstructive Sleep Apnea Agents
- 81. Ophthalmic Antibiotics
- 82. Ophthalmic Antibiotics/Steroid Combinations
- 83. Ophthalmics for Allergic Conjunctivitis
- 84. Ophthalmics, Anti-Inflammatories
- 85. Ophthalmics, Glaucoma Agents
- 86. Opiate Dependence Treatments**
- 87. Oral and Topical Contraceptives
- 88. Otic Antibiotics
- 89. PAH Agents**

- 90. Pancreatic Enzymes
- 91. Pituitary Suppressive Agents, LHRH
- 92. Platelet Aggregation Inhibitors**
- 93. Potassium Removing Agents**
- 94. Progestins for Cachexia
- 95. Proton Pump Inhibitors
- 96. Sedative Hypnotics
- 97. Skeletal Muscle Relaxants
- 98. Steroids, Topical
- 99. Stimulants & Related Agents
- 100. Tetracyclines
- 101. Ulcerative Colitis Agents
- 102. Vaginal Ring Contraceptives
- 103. Vasodilators, Coronary
- 104. VMAT Inhibitors

